bluebird bio Inc (BLUE) – Strategy, SWOT and Corporate Finance Report

bluebird bio Inc (BLUE) – Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company

Key Highlights

bluebird bio Inc (bluebird bio) is a biotechnology company that focuses on the development and commercialization of gene therapies for the treatment of severe genetic diseases and cancer. The company develops its products based on integrated product platforms such as lentiviral gene addition platform, cancer immunotherapy and gene editing. Its product pipeline includes elivaldogene autotemcel for the treatment of cerebral adrenoleukodystrophy (CALD); betibeglogene autotemcel for transfusion-dependent beta thalassemia; Lovo-cel for the treatment of sickle cell disease, besides compounds under development for the treatment of various cancers. The company has collaboration with pharmaceutical companies to discover, develop and commercialize gene therapy products. bluebird bio is headquartered in Cambridge, Massachusetts, the US.

Scope

• Detailed information on bluebird bio Inc required for business and competitor intelligence needs

• A study of the major internal and external factors affecting bluebird bio Inc in the form of a SWOT analysis

• An in-depth view of the business model of bluebird bio Inc including a breakdown and examination of key business segments

• News about bluebird bio Inc, such as business expansion, restructuring, and contract wins

• Large number of easy-to-grasp charts and graphs that present important data and key trends

Reasons to buy

• Track strategic initiatives of the company and latest corporate news and actions.

• Assess bluebird bio Inc as a prospective partner, vendor or supplier.

• Support sales activities by understanding your customers' businesses better.

• Stay up to date on bluebird bio Incs business structure, strategy and prospects.

Note: Some sections may be missing if data is unavailable for the company.

Companies mentioned

Intellia Therapeutics Inc

GlycoMimetics Inc

4SC AG

Beam Therapeutics Inc

Bellicum Pharmaceuticals Inc

Sangamo Therapeutics Inc

Global Blood Therapeutics Inc

Intellia Therapeutics Inc

Sangamo Therapeutics Inc

Bellicum Pharmaceuticals Inc

4SC AG

GlycoMimetics Inc

Beam Therapeutics Inc

Global Blood Therapeutics Inc

Acceleron Pharma Inc

Table of Contents